Drug developer BiVictriX Therapeutics has a low capital cost model which outsources the main operations. The company also works with the University of Liverpool and Swansea University.
BVX001 has already indicated an anti-tumour effect in animal models. No adverse effects were observed. The cash raised will accelerate the optimisation of BVX001, so it reaches pre-clinical milestones. Further cash will be required to commence clinical trials and invest in other potential treatments. Further fundraisings could be dilutive, although the shares got off to a good start.
The share price opene...
